ClinicalTrials.gg
Not yet recruitingNCT07402434ADVANCE-CFTRUpdated Feb 17, 2026

A Prospective Study of Advanced Diagnostics in People With an Unclear Diagnosis of Cystic Fibrosis

An observational study in Cystic Fibrosis (CF) and CFTR-related Disorders, sponsored by Royal Brompton & Harefield NHS Foundation Trust. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Royal Brompton & Harefield NHS Foundation Trust · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Cystic Fibrosis by Royal Brompton & Harefield NHS Foundation Trust — 3 open to participants now, 4 under way, none of them phase 3. Cystic Fibrosis · Royal Brompton & Harefield NHS Foundation Trust.

Started
2026
with 1 other
Observational
5 of 16
2 open now
Registered
15th of 16
by date

Among the 16 studies in Cystic Fibrosis by Royal Brompton & Harefield NHS Foundation Trust, this one is one of 2 that started in 2026, is one of 5 observational ones, and was the 15th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

3 of the 16 studies in Cystic Fibrosis by Royal Brompton & Harefield NHS Foundation Trust are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 16 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Cystic Fibrosis by Royal Brompton & Harefield NHS Foundation Trust, or all of them as a file.
02

Study summary

Sometimes it is very difficult to tell if someone has cystic fibrosis (CF), especially when they have rare CF genes. Without this certainty, they are unlikely to get the correct treatment so their health may be affected. More accurate ways to test for CF are therefore needed in this situation. The aim of this study is to develop a more accurate test using what are called "organoids" or "mini organs." Organoids are grown in the laboratory from a small piece of gut tissue. As they have the person's exact genes, they can show if the CF gene ("CFTR") is working correctly or not and thus if the person has CF. The investigators will compare the organoid response with the current more established tests, such as the sweat test and CF genetics, and other recognised specialist tests called nasal potential difference (NPD) and intestinal current measurement (ICM). The gut tissue is usually taken by a quick, relatively painless, outpatient procedure (rectal biopsy). The additional benefit of organoids is that they can also help us to work out the best treatment for that individual by testing how well the gut tissue responds to different drugs in the laboratory. The investigators wish to carry out this research to prove that gut organoids are a better way to test for CF in this situation. The goal will be to diagnose people faster and for them to get better treatment quicker, both key for leading a longer and healthier life.

Read the detailed description

BACKGROUND The diagnosis of cystic fibrosis (CF) can be difficult in an important minority of individuals (\~10-15% CF diagnoses), particularly when one or two rare variants of the CF gene (cystic fibrosis transmembrane conductance regulator; CFTR) are identified and the sweat test (sweat chloride concentration; SCC) is non-diagnostic. Biomarkers of CFTR function enable the quantification of individual CFTR protein function, the key underlying defect associated with CF. Such biomarkers play an important role in diagnosing CF and have the additional key capability of measuring the treatment benefits of CFTR targeting therapies, such as CFTR modulators. The currently validated biomarkers of CFTR function; such as SCC, nasal potential difference (NPD) and intestinal current measurements (ICM) can accurately characterise individuals at the extreme ranges of CFTR function (healthy and pancreatic insufficient (PI) CF), but are less reliable in intermediate ranges, particularly when clinical features are atypical. This 'difficult diagnosis' can lead to both a false positive and negative diagnostic outcome, with missed opportunities for the introduction of effective treatments, such as CFTR modulators. Some individuals remain undiagnosed for many years, even decades, so significant disease, associated with declining health, can occur. Individuals and their families are often frustrated and disillusioned by years of uncertainty. In addition, there is a group of individuals with a more limited phenotype (e.g. pancreatitis or congenital bilateral absence of the vas deferens, CBAVD), in whom the strict CF diagnostic criteria are not satisfied - their condition is termed CFTR-related disorder (RD). Recent European CF Society (ECFS) guidelines have highlighted an urgent need for a more accurate and streamlined pathway to their diagnosis.

The Difficult CF Diagnosis (DCFD) service at the Royal Brompton Hospital (RBH) uses NPD, along with whole gene analysis of CFTR and other associated genes for diagnosing unclear cases. Intestinal current measurements (ICM) - the assessment of CFTR function in Ussing chambers using ex vivo tissue biopsies of the intestinal epithelium - is currently being set-up. It is well known that an important sub-group of patients remain undiagnosed. More recently, CFTR-dependent tests in patient-derived intestinal organoids (established at the Beekman lab, University Medical Center (UMC) Utrecht University, Utrecht, The Netherlands) were also found to have excellent diagnostic capabilities with the added benefits of providing key phenotyping and prognostic information, using two different techniques - forskolin-induced-swelling (FIS) and morphological analysis (e.g. steady state lumen area, SLA). These both rely on CFTR-dependent ion and fluid secretion into the organoid lumen. Organoids can also quantify individual responses to CFTR modulators in the laboratory for estimation of potential clinical benefit and can be biobanked for future studies. How one should optimally use these different biomarkers in the context of difficult-to-diagnose individuals and treatment thereof with CFTR modulators is unclear.

ADVANCE-CFTR study is a prospective cohort study of 40-50 individuals with difficult-to-diagnose disease. The participants will be recruited from the Difficult CF Diagnosis (DCFD) service of the Royal Brompton Hospital. Up to 15 CF patients and 15 healthy (non-CFTR disease) controls will also be recruited to validate the tests and anchor extremes in the assays.

03

Conditions studied

  • Cystic Fibrosis (CF)
  • CFTR-related Disorders

Browse trials for

Keywords

  • CFTR-related disorders
  • Advanced Diagnostics
  • Personalised medicine
  • Cystic Fibrosis (CF)
  • Nasal potential difference (NPD)
  • Intestinal current measurements (ICM)
  • Organoids
  • Sweat chloride concentration (SCC)
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The investigators aim to recruit 40-50 patients from the DCFD service over a 30 month period. A formal power calculation is not possible due to the exploratory nature of the analyses. Recruitment will be opportunistic, based on estimates from the DCFD service. Up to 15 healthy (non-CFTR disease) and 15 CF controls will also be recruited to validate the tests and anchor extremes in the assays.

Eligibility criteria

Inclusion Criteria:

Group A: Difficult Cystic Fibrosis Diagnosis Cohort

Inclusion criteria:

  1. Patients with difficult-to-diagnose CF*
  2. Adults (≥16y)
  3. Willing to undergo rectal
  4. Able to comply with the study

    • Definition: Non-diagnostic CFTR testing (individuals who do not fulfil CF diagnostic criteria [2 CF-causing CFTR variants and/or sweat chloride concentration ≥60 mmol/L]). Of note, there are some individuals with \<2 CF-causing CFTR variants after extended CFTR genetic analysis but with a SCC >60mmol/L. Expansion of the patient pool to include these is permissible.

Group B: Cystic Fibrosis Patient Cohort

Inclusion criteria:

  1. Patients with confirmed Cystic Fibrosis
  2. Adults (≥16y)
  3. Willing to undergo rectal biopsy for this study
  4. Able to comply with the study

Group C: Non-Cystic Fibrosis Patient Cohort

Inclusion criteria:

  1. Patients without Cystic Fibrosis or CFTR-related disorder
  2. Adults (≥16y)
  3. Willing to undergo rectal biopsy for this study (if undergoing a lower GI endoscopy for other purposes)
  4. Able to comply with the study

Exclusion Criteria:

Group A: Difficult Cystic Fibrosis Diagnosis Cohort

Exclusion criteria:

  1. to rectal biopsy (e.g. significant bleeding diathesis)
  2. History of lung transplantation
  3. Receiving CFTR modulator treatment
  4. Current participation (or participation within one month of enrolment) in a clinical trial of an medicinal product which affects CFTR function (e.g. CFTR modulators, genetic therapies)
  5. Female who is pregnant or breastfeeding
  6. Unable to provide

Group B: Cystic Fibrosis Patient Cohort

Exclusion criteria:

  1. Contra-indication to rectal biopsy (e.g. significant bleeding diathesis)
  2. Current participation (or participation within one month of enrolment) in a clinical trial of an investigational medicinal product which affects CFTR function (e.g. CFTR modulators, genetic therapies)
  3. Female who is pregnant or breastfeeding
  4. Unable to provide informed consent
  5. Exclude all subjects where diagnosis of CF is in doubt

Group C: Non-Cystic Fibrosis Patient Cohort

Exclusion criteria:

  1. Contra-indication to rectal biopsy (e.g. significant bleeding diathesis)
  2. Female who is pregnant or breastfeeding
  3. Unable to provide informed consent
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Group A - Difficult Cystic Fibrosis Diagnosis Cohort

    'Difficult-to-diagnose' patients will be recruited from the 'Difficult CF Diagnosis' service via our established referral pathway. These patients will have non-diagnostic first line CFTR testing (individuals who do not fulfil CF diagnostic criteria \[2 CF-causing CFTR gene variants and/or sweat chloride concentration ≥60 mmol/L\]) . These patients will be 16 years or older and will be willing to undergo a rectal biopsy.

    Procedure: Rectal Biopsy

  • Group B - Cystic Fibrosis Patient Cohort

    Patients aged 16 years or older with a confirmed Cystic Fibrosis diagnosis. They would need to be willing to undergo a rectal biopsy.

    Procedure: Rectal Biopsy

  • Group C - Non-Cystic Fibrosis Patient Cohort

    Patients aged 16 years or older without a Cystic Fibrosis or CFTR-related disorder diagnosis who would be willing to undergo a rectal biopsy for this study (if undergoing a lower GI endoscopy for other purposes).

    Procedure: Rectal biopsy taken opportunistically during endoscopy procedure for other reasons. · Genetic: Blood test for CFTR Genotyping

Interventions

  • ProcedureRectal Biopsy

    Rectal biopsy sampling will be performed using either forceps or a suction device according to the method of Vonk et al (2020). Rectal biopsies will be obtained by trained and competent personnel in an appropriate setting, patients recruited will be fully informed and will have provided written consent. Once biopsy samples have been taken the resulting tissue will be processed, stored and transported using established laboratory protocols. The rectal tissue collected will be used to perform intestinal current measurements and create organoids or 'mini-organs' to allow CFTR protein function to be further characterised.

  • ProcedureRectal biopsy taken opportunistically during endoscopy procedure for other reasons.

    Rectal Biopsy tissue samples will be taken opportunistically for this patient cohort who are undergoing an endoscopy for other reasons. Rectal biopsies will be obtained by trained and competent personnel in an appropriate setting, patients recruited will be fully informed and will have provided written consent. The rectal tissue collected will be used to perform intestinal current measurements and create organoids or 'mini-organs' to allow CFTR protein function to be further characterised.

  • GeneticBlood test for CFTR Genotyping

    Blood test for CFTR genotyping will be taken for Group C patients to ensure these patients are 'healthy controls' and that they do not have any CFTR gene variants associated with CF.

06

What researchers measure

Primary outcomes

  1. Quantitative assessment of CFTR function

    The primary outcome is a single or composite measurement of CFTR function derived from organoid function, Sweat Chloride Concentration (SCC), Nasal Potential Difference (NPD), and Intestinal Current Measurements (ICM). These quantitative values are then used to correlate with clinical phenotype and final diagnosis, but the outcome measure itself is CFTR functional measurement across the four test modalities.

    Time frame: 30 months

Secondary outcomes

  1. To individually phenotype patients with difficult-to-diagnose CF

    To measure individual CFTR function in people with difficult-to-diagnose disease using multiple CFTR functional assays (organoids (Forskolin-induced-swelling assays and AI morphological analysis), Sweat chloride concentration, Nasal potential difference measurements and Intestinal current measurements), and to correlate this with their clinical phenotype, genotype and final diagnosis.

    Time frame: 30 months

  2. CFTR modulator response in intestinal organoids

    To measure CFTR modulator responses of intestinal organoids derived from individuals with difficult to-diagnose disease, taken by rectal biopsy. Response will be measured using Forskolin-induced-swelling assays and AI morphological analysis.

    Time frame: 30 months

07

Study locations

1 site
08

References and documents

Publications

  • Wilschanski M, Famini H, Strauss-Liviatan N, Rivlin J, Blau H, Bibi H, Bentur L, Yahav Y, Springer H, Kramer MR, Klar A, Ilani A, Kerem B, Kerem E. Nasal potential difference measurements in patients with atypical cystic fibrosis. Eur Respir J. 2001 Jun;17(6):1208-15. doi: 10.1183/09031936.01.00092501. PubMed 11491166 ↗
  • De Jonge HR, Ballmann M, Veeze H, Bronsveld I, Stanke F, Tummler B, Sinaasappel M. Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. J Cyst Fibros. 2004 Aug;3 Suppl 2:159-63. doi: 10.1016/j.jcf.2004.05.034. PubMed 15463951 ↗
  • www.cftr2.com
  • Waller MD, Simmonds NJ. Phenotypic variability of R117H-CFTR expression within monozygotic twins. Paediatr Respir Rev. 2016 Aug;20 Suppl:21-3. doi: 10.1016/j.prrv.2016.06.009. Epub 2016 Jun 15. PubMed 27364092 ↗
  • Servidoni MF, Sousa M, Vinagre AM, Cardoso SR, Ribeiro MA, Meirelles LR, de Carvalho RB, Kunzelmann K, Ribeiro AF, Ribeiro JD, Amaral MD. Rectal forceps biopsy procedure in cystic fibrosis: technical aspects and patients perspective for clinical trials feasibility. BMC Gastroenterol. 2013 May 20;13:91. doi: 10.1186/1471-230X-13-91. PubMed 23688510 ↗
  • Cuyx S, Ramalho AS, Corthout N, Fieuws S, Furstova E, Arnauts K, Ferrante M, Verfaillie C, Munck S, Boon M, Proesmans M, Dupont L, De Boeck K, Vermeulen F; Belgian Organoid Project. Rectal organoid morphology analysis (ROMA) as a promising diagnostic tool in cystic fibrosis. Thorax. 2021 Nov;76(11):1146-1149. doi: 10.1136/thoraxjnl-2020-216368. Epub 2021 Apr 15. PubMed 33859053 ↗
  • Beekman JM, Sermet-Gaudelus I, de Boeck K, Gonska T, Derichs N, Mall MA, Mehta A, Martin U, Drumm M, Amaral MD. CFTR functional measurements in human models for diagnosis, prognosis and personalized therapy: Report on the pre-conference meeting to the 11th ECFS Basic Science Conference, Malta, 26-29 March 2014. J Cyst Fibros. 2014 Jul;13(4):363-72. doi: 10.1016/j.jcf.2014.05.007. Epub 2014 Jun 2. No abstract available. PubMed 24882694 ↗
  • Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M, Rosenfeld M, Sermet-Gaudelus I, Southern KW, Marshall BC, Sosnay PR. Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017 Feb;181S:S4-S15.e1. doi: 10.1016/j.jpeds.2016.09.064. PubMed 28129811 ↗
  • Hug MJ, Derichs N, Bronsveld I, Clancy JP. Measurement of ion transport function in rectal biopsies. Methods Mol Biol. 2011;741:87-107. doi: 10.1007/978-1-61779-117-8_7. PubMed 21594780 ↗
  • Solomon GM, Bronsveld I, Hayes K, Wilschanski M, Melotti P, Rowe SM, Sermet-Gaudelus I. Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD). J Vis Exp. 2018 Sep 13;(139):57006. doi: 10.3791/57006. PubMed 30272672 ↗
  • Dekkers JF, Alieva M, Wellens LM, Ariese HCR, Jamieson PR, Vonk AM, Amatngalim GD, Hu H, Oost KC, Snippert HJG, Beekman JM, Wehrens EJ, Visvader JE, Clevers H, Rios AC. High-resolution 3D imaging of fixed and cleared organoids. Nat Protoc. 2019 Jun;14(6):1756-1771. doi: 10.1038/s41596-019-0160-8. Epub 2019 May 3. PubMed 31053799 ↗
  • Vonk AM, van Mourik P, Ramalho AS, Silva IAL, Statia M, Kruisselbrink E, Suen SWF, Dekkers JF, Vleggaar FP, Houwen RHJ, Mullenders J, Boj SF, Vries R, Amaral MD, de Boeck K, van der Ent CK, Beekman JM. Protocol for Application, Standardization and Validation of the Forskolin-Induced Swelling Assay in Cystic Fibrosis Human Colon Organoids. STAR Protoc. 2020 Jun 3;1(1):100019. doi: 10.1016/j.xpro.2020.100019. eCollection 2020 Jun 19. PubMed 33111074 ↗
  • Rowe SM, Clancy JP, Wilschanski M. Nasal potential difference measurements to assess CFTR ion channel activity. Methods Mol Biol. 2011;741:69-86. doi: 10.1007/978-1-61779-117-8_6. PubMed 21594779 ↗
  • Boj SF, Vonk AM, Statia M, Su J, Vries RR, Beekman JM, Clevers H. Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients. J Vis Exp. 2017 Feb 11;(120):55159. doi: 10.3791/55159. PubMed 28287550 ↗
  • Morris-Rosendahl DJ, Edwards M, McDonnell MJ, John S, Alton EWFW, Davies JC, Simmonds NJ. Whole-Gene Sequencing of CFTR Reveals a High Prevalence of the Intronic Variant c.3874-4522A>G in Cystic Fibrosis. Am J Respir Crit Care Med. 2020 Jun 1;201(11):1438-1441. doi: 10.1164/rccm.201908-1541LE. No abstract available. PubMed 32017858 ↗
  • Cirilli N, Southern KW, Barben J, Vermeulen F, Munck A, Wilschanski M, Nguyen-Khoa T, Aralica M, Simmonds NJ, De Wachter E; ECFS Diagnostic Network Working Group. Standards of care guidance for sweat testing; phase two of the ECFS quality improvement programme. J Cyst Fibros. 2022 May;21(3):434-441. doi: 10.1016/j.jcf.2022.01.004. Epub 2022 Jan 19. PubMed 35063396 ↗
  • Dekkers JF, Berkers G, Kruisselbrink E, Vonk A, de Jonge HR, Janssens HM, Bronsveld I, van de Graaf EA, Nieuwenhuis EE, Houwen RH, Vleggaar FP, Escher JC, de Rijke YB, Majoor CJ, Heijerman HG, de Winter-de Groot KM, Clevers H, van der Ent CK, Beekman JM. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci Transl Med. 2016 Jun 22;8(344):344ra84. doi: 10.1126/scitranslmed.aad8278. PubMed 27334259 ↗
  • de Winter-de Groot KM, Janssens HM, van Uum RT, Dekkers JF, Berkers G, Vonk A, Kruisselbrink E, Oppelaar H, Vries R, Clevers H, Houwen RHJ, Escher JC, Elias SG, de Jonge HR, de Rijke YB, Tiddens HAWM, van der Ent CK, Beekman JM. Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function. Eur Respir J. 2018 Sep 17;52(3):1702529. doi: 10.1183/13993003.02529-2017. Print 2018 Sep. PubMed 30166324 ↗
  • Muilwijk D, de Poel E, van Mourik P, Suen SWF, Vonk AM, Brunsveld JE, Kruisselbrink E, Oppelaar H, Hagemeijer MC, Berkers G, de Winter-de Groot KM, Heida-Michel S, Jans SR, van Panhuis H, van der Eerden MM, van der Meer R, Roukema J, Dompeling E, Weersink EJM, Koppelman GH, Vries R, Zomer-van Ommen DD, Eijkemans MJC, van der Ent CK, Beekman JM. Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression. Eur Respir J. 2022 Aug 18;60(2):2100508. doi: 10.1183/13993003.00508-2021. Print 2022 Aug. PubMed 35086832 ↗
  • Derichs N, Sanz J, Von Kanel T, Stolpe C, Zapf A, Tummler B, Gallati S, Ballmann M. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. Thorax. 2010 Jul;65(7):594-9. doi: 10.1136/thx.2009.125088. PubMed 20627915 ↗
  • Castellani C, De Boeck K, De Wachter E, Sermet-Gaudelus I, Simmonds NJ, Southern KW; ECFS Diagnostic Network Working Group. ECFS standards of care on CFTR-related disorders: Updated diagnostic criteria. J Cyst Fibros. 2022 Nov;21(6):908-921. doi: 10.1016/j.jcf.2022.09.011. Epub 2022 Oct 8. PubMed 36220763 ↗
  • Simmonds NJ. Is it cystic fibrosis? The challenges of diagnosing cystic fibrosis. Paediatr Respir Rev. 2019 Aug;31:6-8. doi: 10.1016/j.prrv.2019.02.004. Epub 2019 Feb 28. PubMed 30967347 ↗
  • Balfour-Lynn IM, Puckey M, Simmonds NJ, Davies JC. Revisiting a diagnosis of cystic fibrosis - Uncertainties and considerations. Paediatr Respir Rev. 2022 Jun;42:29-34. doi: 10.1016/j.prrv.2021.11.002. Epub 2021 Dec 8. PubMed 34998674 ↗
  • Barry PJ, Simmonds NJ. Diagnosing Cystic Fibrosis in Adults. Semin Respir Crit Care Med. 2023 Apr;44(2):242-251. doi: 10.1055/s-0042-1759881. Epub 2023 Jan 9. PubMed 36623819 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Jun 2028, 27 months later.

Of 228 non-industry observational studies under Cystic Fibrosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 89. This study's planned 27 months is below that.

Counting every sponsor, half of 243 studies reached it within 41 months; a quarter within 19 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 11, 2026
StartEst.
Feb 2, 2026
Primary completionEst.
Jun 1, 2028
CompletionEst.
Sep 1, 2028
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07402434
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
Feb 2, 2026 (estimated)
Primary completion
Jun 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Feb 17, 2026

Study contacts

Emma C Russell-Jones, MBBS
Contact
emma.russell-jones@nhs.net
02073528121 ext. 88940
Nicholas J Simmonds
principal investigator · Royal Brompton Hospital and Imperial College London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion